OM:HEMC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Hemcheck Sweden AB (publ) operates as a medical technology company in Sweden. More Details


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has Hemcheck Sweden's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HEMC's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.2%

HEMC

-1.4%

SE Medical Equipment

-2.4%

SE Market


1 Year Return

-7.7%

HEMC

19.0%

SE Medical Equipment

16.8%

SE Market

Return vs Industry: HEMC underperformed the Swedish Medical Equipment industry which returned 19% over the past year.

Return vs Market: HEMC underperformed the Swedish Market which returned 16.8% over the past year.


Shareholder returns

HEMCIndustryMarket
7 Day7.2%-1.4%-2.4%
30 Day-5.8%0.8%1.4%
90 Day-20.3%15.6%11.8%
1 Year-7.7%-7.7%20.9%19.0%18.9%16.8%
3 Year-74.7%-74.7%71.4%51.1%31.9%17.8%
5 Yearn/a100.4%66.5%69.4%36.4%

Price Volatility Vs. Market

How volatile is Hemcheck Sweden's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Hemcheck Sweden undervalued compared to its fair value and its price relative to the market?

1.25x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate HEMC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate HEMC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: HEMC is unprofitable, so we can't compare its PE Ratio to the SE Medical Equipment industry average.

PE vs Market: HEMC is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HEMC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HEMC is good value based on its PB Ratio (1.3x) compared to the SE Medical Equipment industry average (4.9x).


Next Steps

Future Growth

How is Hemcheck Sweden forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hemcheck Sweden has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Hemcheck Sweden performed over the past 5 years?

-21.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HEMC is currently unprofitable.

Growing Profit Margin: HEMC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HEMC is unprofitable, and losses have increased over the past 5 years at a rate of 21.1% per year.

Accelerating Growth: Unable to compare HEMC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HEMC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17.2%).


Return on Equity

High ROE: HEMC has a negative Return on Equity (-21.79%), as it is currently unprofitable.


Next Steps

Financial Health

How is Hemcheck Sweden's financial position?


Financial Position Analysis

Short Term Liabilities: HEMC's short term assets (SEK13.1M) exceed its short term liabilities (SEK2.9M).

Long Term Liabilities: HEMC's short term assets (SEK13.1M) exceed its long term liabilities (SEK82.6K).


Debt to Equity History and Analysis

Debt Level: HEMC's debt to equity ratio (1.1%) is considered satisfactory.

Reducing Debt: HEMC's debt to equity ratio has reduced from 52.8% to 1.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HEMC has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: HEMC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 24.3% each year


Next Steps

Dividend

What is Hemcheck Sweden current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HEMC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HEMC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HEMC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HEMC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HEMC's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average management tenure


CEO

Joen Averstad

1.33yrs

Tenure

Mr. Joen Averstad serves as a Chief Executive Officer at Hemcheck Sweden AB (publ) since May 2019.


Leadership Team

NamePositionTenureCompensationOwnership
Joen Averstad
Chief Executive Officer1.33yrsno datano data
Robert Thoren
Chief Financial Officer4.67yrsno datano data
Bjorn Eriksson
Chief Technology Officer6.67yrsno datano data
Peter Andersson
Sales & Marketing Manager and Deputy CEO2.67yrsno datano data

3.7yrs

Average Tenure

Experienced Management: HEMC's management team is considered experienced (3.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Hjalmar Didrikson
Director10.67yrsno data1.45%
SEK 707.2k
Måns Alfvén
Deputy Director5.67yrsno datano data
Torbjörn Koivisto
Independent Director4.67yrsno datano data
Karin Dahllof
Independent Director2.67yrsno datano data
Jenni Bjornulfson
Independent Director4.67yrsno datano data
Anna Dalgaard
Independent Chairman2.67yrsno datano data

4.7yrs

Average Tenure

47.5yo

Average Age

Experienced Board: HEMC's board of directors are considered experienced (4.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Hemcheck Sweden AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hemcheck Sweden AB (publ)
  • Ticker: HEMC
  • Exchange: OM
  • Founded: 2010
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: kr48.853m
  • Shares outstanding: 15.71m
  • Website: https://www.hemcheck.com

Number of Employees


Location

  • Hemcheck Sweden AB (publ)
  • Karlstads universitet
  • Biomedicin
  • Karlstad
  • Värmland County
  • 651 88
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HEMCOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKMar 2017

Biography

Hemcheck Sweden AB (publ) operates as a medical technology company in Sweden. The company develops and commercializes Helge, which detects hemolysis in blood samples at the point of care. It serves emergen ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/27 04:28
End of Day Share Price2020/09/25 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.